Through this partnership Genome Canada will implement an important element of its Strategic Plan (2012-2017) and CIHR will launch its Personalized Medicine Signature Initiative. This strategic partnership will build on the complementary mandates of Genome Canada and CIHR and provide an opportunity to maximize the effectiveness of the research communities, infrastructure and resources supported by both organizations.
In the context of this competition Personalized Health can be seen as a more evidence based approach to decision making both with regards to health maintenance and disease interventions. There is a spectrum of activities that span what is referred to as the molecular medicine continuum from health maintenance and disease prevention, through early detection, to treatment of disease and disease prognosis (see Fig. 1). This approach relies upon an increasing knowledge of the underlying risk factors, causes, and mechanisms of disease pathogenesis as well as an understanding of the influence of environment, behaviour and lifestyle on the onset and outcomes of the disease state.
Call for Proposals
Guidelines
Génome Québec Guidelines
Pre-Application Evaluation Criteria
Co-Funding Opportunities
Application Form
Budget Template